An open-label pilot study to evaluate a flexible dosing regimen of epoetin alfa for the treatment of chemotherapy-induced anemia: 60,000 Units weekly followed by 60,000 units every 2 weeks

Supportive Cancer Therapy

Volumn 4, Issue 1, 2006, Pages 56-62

  Reddy, Prabhakara K ^b   Williams, Denise ^c   Wilhelms, Francois E ^a  

^a Ortho Biotech Products LP   (United States)

^b St Joseph's Mercy Health Center Hot Springs   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Hematologic response; Red blood cells; Solid tumors; Thrombotic vascular events

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

AGED; ANEMIA; ARTICLE; ASTHENIA; BRAIN INFARCTION; BRAIN ISCHEMIA; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; SINGLE BLIND PROCEDURE; SUPERFICIAL THROMBOPHLEBITIS; THORAX PAIN; THROMBOSIS;

EID: 33751181640     PISSN: 15432912     EISSN: None     Source Type: Journal    
DOI: 10.3816/SCT.2006.n.032     Document Type: Article

References (16)

1. Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer 1993; 29A(suppl 2):S2-S8.
2. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997; 15:1218-1234.
3. Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998; 16:3412-3425.
4. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19:2875-2882.
5. Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005; 23:2606-2617.
6. Gregory SA, Xie J, Woodman RC. Maintenance dosing with epoetin alfa every two weeks (Q2W) in anemic patients with cancer receiving chemotherapy every one or four weeks: final results. Blood 2005; 106:21b (Abstract #3770).
7. Montoya VP, Xie J, Woodman RC. Maintenance dosing with epoetin alfa every three weeks (Q3W) in anemic patients with cancer receiving chemotherapy every three weeks: final results. Blood 2005; 106:992a (Abstract #3555).
8. Patton J, Kuzur M, Liggett W, et al. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy. Oncologist 2004; 9:90-96.
9. Steensma DP, Molina R, Sloan JA, et al. Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer. J Clin Oncol 2006; 24:1079-1089.
10. Procrit® [package insert]. Raritan, NJ: Ortho Biotech Products, LP; 2005.
11. Cheung WK, Danneman B, Wacholtz M, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of epoetin alfa in anemic cancer patients receiving cycling chemotherapy. Blood 2004; 104:111b (Abstract #4101).
12. Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin -α increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 2003; 98:1072-1079.
13. Rodgers GM III, Cella D, Chanan-Khan A, et al. Cancer- and treatment-related anemia. National Comprehensive Cancer Network, Inc. NCCN Clinical Practice Guidelines in Oncology™, v.2.2006. Available at: http://www.nccn.org. Accessed May 17, 2006.
14. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362:1255-1260.
15. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005; 23:5960-5972.
16. Henry DH, Gordan LN, Charu V, et al. Randomized, open-label comparison of epoetin alfa extended dosing (80,000 U Q2W) vs weekly dosing (40,000 U QW) in patients with chemotherapy-induced anemia. Curr Med Res Opin 2006; 22:1403-1413.